# ARTnet Perspectives and Contributions to Theranostics

## TL;DR

This paper discusses the development and impact of ARTnet, a clinical trials network in Australia focused on radiopharmaceuticals and theranostics.

## Contribution

The paper highlights ARTnet's role in advancing theranostics through multicenter clinical trials and regulatory approvals.

## Key findings

- ARTnet has supported impactful, prospective clinical trials in radiopharmaceuticals.
- Australia has played a key role in generating evidence for theranostic safety and efficacy.
- ARTnet's operations have contributed to international regulatory approvals and healthcare funding.

## Abstract

Theranostics is a rapidly growing field, providing new therapeutic options for cancer patients. Clinical trials have a key role in establishing the efficacy and safety of new treatments and determining impact on patient care. Multicenter clinical trials with radiopharmaceuticals provide robust data to support clinical implementation; however, there are important considerations to ensure high-quality and reliable clinical data.

Australasian Radiopharmaceutical Trials Network (ARTnet) is a multidisciplinary clinical trials network established in 2014 to facilitate multicenter clinical trials with radiopharmaceuticals in Australia. Over the last decade, ARTnet has supported impactful, prospective clinical trials through quality activities and engagement. In theranostics, Australia has had a key role in clinical translation and generating evidence for safety and efficacy, resulting in regulatory approval and health care funding internationally. This report describes the development of ARTnet as a clinical trials network, highlighting the intent, current status, and operations of ARTnet, with a particular focus on theranostics.